PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10537449
Filing Date	2006-01-09
First Named Inventor	Bernd Schwenzer
Art Unit	1635
Examiner Name	Dana H Shin
Attorney Docket Number	101215-189

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
/DS/	1	5489508		1996-02-06	West et al.	Entire document.
/DS/	2	5645986		1997-07-08	West et al.	Entire document.

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
/DS/	1	20020045588	A1	2002-04-18	Monia et al.	Entire document.

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
/DS/	1	0 666 313	EP	A2	1995-08-09	Univ Iowa Res Found	Entire document.	☒
/DS/	2	98 28442	WO		1998-07-02	Geron Corporation	Entire document.	☒

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10537449
	Filing Date	2006-01-09
	First Named Inventor	Bernd Schwenzer
	Art Unit	1635
	Examiner Name	Dana H Shin
	Attorney Docket Number	101215-189

/DS/	3	97 37691	WO		1997-10-16	Lynx Therapeutics Inc.	Entire document.	☒
/DS/	4	01 88198	WO	A	2001-11-22	Monia Brett P.	Entire document. Cited in International Search Report. Copy of document not provided.	☐
/DS/	5	99 50279	WO	A	1999-10-07	Lingner Joachim	Entire document. Cited in International Search Report. Copy of document not provided.	☐

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
/DS/	1	SCHINDLER ASCAN ET AL.; "Human telomerase reverse transcriptase antisense treatment downregulates the viability of prostate cancer cells in vitro"; International Journal of Oncology; volume 19, no. 1, July 2001, pages 25-30. Entire document. Cited in International Search Report. Copy of document not provided.	☐
/DS/	2	ZHANG Y ET AL.; "Effect of antisense hTERT mRNA oligodeoxynucleotide on telomerase activity of leukemic cells"; Cell Biology International; volume 26, no. 5, May 2002, pages 427-431. Entire document. Cited in International Search Report. Copy of document not provided.	☐
/DS/	3	KOGA S ET AL.; "Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA"; Gene Therapy; volume 8, no. 8, April 2001; pages 654-658. Entire document. Cited in International Search Report. Copy of document not provided.	☐
/DS/	4	SARTEZKI GABRIELE ET AL.; "Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells"; Cancer Gene Therapy; volume 8, no. 10, October 2001, pages 827-834. Entire document. Cited in International Search Report. Copy of document not provided.	☐
/DS/	5	YOKOYAMA YASUHIRO ET AL.; "The 5'-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity"; Biochemical and Biophysical Research Communications; volume 273, no. 1, June 24, 2000, pages 316-321. Entire document. Cited in International Search Report. Copy of document not provided.	☐
/DS/	6	SCHERR MICHAELA ET AL; "RNA accessibility prediction: A theoretical approach is consistent with experimental studies in cell extracts"; Nucleic Acids Research; volume 28, no. 13, July 1, 2000; pages 2455-2461. Entire document. Cited in International Search Report. Copy of document not provided.	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10537449
	Filing Date	2006-01-09
	First Named Inventor	Bernd Schwenzer
	Art Unit	1635
	Examiner Name	Dana H Shin
	Attorney Docket Number	101215-189

/DS/	7	PATZEL V ET AL; "A Theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability"; Nucleic Acids Research, Oxford University Press, Surrey, GB; volume 27, no. 22, November 15, 1999, pages 4328-4334. Entire document. Cited in International Search Report. Copy of document not provided.	☐
/DS/	8	WHITE LAURA K ET AL.; "Telomerase inhibitors"; Trends in Biotechnology; volume 19, no. 3, March 2001, pages 114-120. Entire document. Cited in International Search Report. Copy of document not provided.	☐
/DS/	9	KRAEMER KAI ET AL; "Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells"; Clinical Cancer Research: An Official Journal of the American Association for Cancer Research; September 1, 2003, volume 9, no. 10, PT 1, pages 3794-3800. Entire document. Cited in International Search Report. Copy of document not provided.	☐

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature	/Dana Shin/	Date Considered	04/26/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.